Xortx Therapeutics Inc. Stock
€0.81
Your prediction
Financial data and news for Xortx Therapeutics Inc.
sharewise wants to provide you with the best news and tools for Xortx Therapeutics Inc., so we directly link to the best financial data sources.
Financials
News
XORTX Announces USD $3 Million Offering
- Proceeds will be used to advance XORTX’s programs for gout -
CALGARY, AB – May 19, 2025 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt:
XORTX Provides Update on FDA Type B Meeting Request
XORTX will focus on key steps to advance a NDA filing for Gout indication
CALGARY, AB – April 30, 2025 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX |
XORTX Announces Grant of European Patent
- Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease Programs -
CALGARY, AB – April 28, 2025 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX |
XORTX Announces Update for Discussion with the FDA
- Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA
CALGARY, AB – March 19, 2025 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Fr
XORTX Commences Gout Program NDA Discussions with the FDA
- Type C Meeting Requested to Accelerate XRx-026 for Gout to NDA
CALGARY, AB – February 24, 2025 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX |